Shares of Apogee Therapeutics, Inc. (APGE) touched a new high of $82.90 yesterday, marking a significant rebound from their 52-week low of $26.20 set last April. Apogee is a clinical-stage biotechnology company advancing differentiated biologics for inflammatory and immune-mediated diseases with high unmet need.The company's lead drug candidate is Zumilokibart (APG777), a half-life extended monoc...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.